ESMO BC 2024

ESMO BC 2024
May 15-17, 2024
Berlin, Germany

European Society for Medical Oncology Breast Cancer 2024.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (2)

    The impact of high body mass index on the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from ASCENT

    • Author(s): Estévez, L
    • trodelvy
    • Oncology
    • mTNBC
    • ASCENT
    • Body Mass Index (BMI)
    • Weight
    • Underweight
    • Overweight
    • Obese

    Efficacy of sacituzumab govitecan versus treatment of physicians' choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials 

    • Author(s): Gluz, O
    • trodelvy
    • Oncology
    • Trop-2
    • HR+/HER2-
    • EVER-132-002
    • meta-analysis
    • Asia
    • CDK4/6i